Exploration and Characterization Ofintratumoral Electrophysiological Heterogeneity in Gliomas Using Magnetoencephalography

NCT07616726 | Not Yet Recruiting

• 2 other identifiers: 69HCL26_00202026-A01156-45
• Study Type: interventional
• Target: 60
• Locations: 1 country
• Sites: 1

Brief Summary

With more than 3,000 new cases per year in France, malignant gliomas are the most common malignant brain tumors in adults. Treatment consists of surgical removal when possible. If this is not possible, a biopsy is performed to obtain a definitive anatomical and molecular diagnosis. Standard medical management after removal or biopsy is based on radio-chemotherapy. Despite this multimodal treatment, progression is the norm due to the invasive nature of these tumors. The prognosis remains very poor, with a median overall survival of around 18 months for glioblastomas. Recent preliminary data indicate that magnetoencephalography (MEG) recordings can identify functional heterogeneity within a glioma. Functional analysis of these two types of areas has shown that the expression of synaptogenic factors is increased in areas of high functional connectivity compared to areas of low functional connectivity. Areas of high functional connectivity are more aggressive and more resistant to treatment. In general, gliomas are characterized by a high degree of inter- and intra-tumoral heterogeneity. The latter has been well characterized at the transcriptomic level, and several distinct cell subpopulations have been described (classical, mesenchymal, proneural) This intra-tumoral heterogeneity is one of the factors contributing to resistance to current therapies, but it remains incompletely understood and explored. MEG is a tool capable of exploring intra- and inter-tumor heterogeneity from an electrophysiological perspective. This represents an original approach that will provide a better understanding of intra-tumor heterogeneity and lead to new therapeutic perspectives.

Conditions

Patients Diagnosed With a Malignant Glioma

Keywords

Glioma; Magnetoencephalography; Intra-tumoral heterogeneity; Feasibility; Radiological patterns

Outcome Measures

Primary Outcomes (1)

• Assess the technical feasibility of studying tumor electrophysiological heterogeneity using magnetoencephalography (MEG) in a series of patients with glioma at the initial stage of treatment.

  Percentage of patients with a complete and usable magnetoencephalography (MEG) recording, allowing intra- and peri-tumoral electrophysiological data to be collected and resting functional connectivity to be studied for all areas of the brain.

  At baseline and during the 10 days prior to the date of surgery, according to the standard of care.

Secondary Outcomes (2)

• Define the radiological characteristics of the different types of areas of interest identified by MEG by comparing MEG mapping and preoperative MRI (anatomical and functional).

  At baseline and during the 10 days prior to the date of surgery, according to the standard of care.

• Define the prognostic impact of ablation of areas with different electrophysiological properties, using an analysis that integrates MEG mapping data, post-operative MRI data, and survival data.

  At baseline and during the 10 days prior to the date of surgery, according to the standard of care.

Study Arms (1)

magnetoencephalography (MEG)

EXPERIMENTAL

Every patients eligible for a glioma resection surgery

Device: MEG

Interventions

MEG DEVICE

Eligible patients will undergo a complete Magnetoencephalography, of approximatively 45min

magnetoencephalography (MEG)

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Male or female aged over 18
• With a newly diagnosed malignant glioma based on brain imaging
• Eligible for surgical removal
• Having given their consent

You may not qualify if:

• Contraindications to Magnetic resonance imaging (MRI) (claustrophobia, metallic implants, particularly intraocular implants, pacemakers)
• Contraindications to magnetoencephalography (MEG) (metallic implants in the mouth-dentures, fillings, crowns)
• Coagulation disorders
• Pregnancy, breastfeeding, or patients not using effective contraception
• Subjects deprived of their liberty by judicial or administrative decision
• Subjects receiving psychiatric care
• Subjects admitted to a health or social care facility for purposes other than research
• Adult subjects subject to legal protection measures (guardianship, curatorship)
• Subjects not affiliated with a social security system or beneficiaries of a similar system

Sponsors & Collaborators

• Hospices Civils de Lyon: lead

Study Sites (1)

Hospices Civils de Lyon

Bron, 69800, France

Location

MeSH Terms

Conditions

Glioma

Condition Hierarchy (Ancestors)

Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue

Central Study Contacts

Thiébaud PICART

CONTACT

04 72 38 49 76; thiebaud.picart@chu-lyon.fr

Julien BERTHILLER

CONTACT

04 27 85 63 01; julien.berthiller@chu-lyon.fr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NA
• Masking: NONE
• Purpose: DIAGNOSTIC
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 18, 2026
• First Posted: June 1, 2026
• Study Start (Estimated): July 1, 2026
• Primary Completion (Estimated): July 1, 2029
• Study Completion (Estimated): December 1, 2029
• Last Updated: June 1, 2026

Record last verified: 2026-05

Locations

FR (1)